NCT04835805 - A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Melanoma

Interventions

DRUG

Belvarafenib

Twice daily (BID), continuous dosing

DRUG

Cobimetinib

Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off

DRUG

Nivolumab

Once every 4 weeks (Q4W)

Trial Locations (16)

2298

Calvary Mater Newcastle, Waratah

3000

Peter MacCallum Cancer Centre-East Melbourne, Melbourne

6009

Linear Clinical Research Ltd, Nedlands

10021

Memorial Sloan Kettering, New York

12203

Charité - Universitätsmedizin Berlin, Berlin

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

21231

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

63110

Washington University School of Medicine, St Louis

68167

Klinikum Mannheim GmbH Universitätsklinikum, Mannheim

72076

Universitatsklinikum Tubingen, Tübingen

80045

University of Colorado Cancer Center, Aurora

94115

California Pacific Medical Center Research Institute, San Francisco

94158

UCSF Helen Diller Family CCC, San Francisco

K1H 8M2

Ottawa Hospital Regional Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

05505

Asan Medical Center - PPDS, Seoul